, Volume 38, Issue 6, pp 537–541 | Cite as

Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective

  • V. Aslanian
  • H. Lemaignen
  • P. Bunouf
  • M. G. Svaland
  • A. Borseth
  • B. Lundby
Diagnostic Neuroradiology


Gadodiamide injection is a new nonionic paramagnetic, extracellular contrast medium. Its safety at a dose of 0.1 mmol/kg body weight was evaluated in a large European multicentre trial on adults referred for contrast-enhanced MRI of the central nervous system. Safety analysis was performed on 2102 patients, in whom adverse events during and up to 24 h after injection were recorded. Adverse events related or possibly related to gadodiamide injection were observed in 102 patients. Injection-associated reactions classified as discomfort (sensation of heat or coldness, pain or pressure at the injection site) occurred in 37 patients (1.8%) and other adverse events (e. g. headache, nausea) were observed in 65 patients (3.1%). No serious adverse event was reported. Efficacy analysis, performed on 2273 patients, and based on comparison of T1- and T2-weighted images before and T1-weighted images after injection showed that more diagnostic information was obtained after gadodiamide injection in 1424 (62.6%) patients; management of 386 (17.0%) patients was affected by the new information give and that a new diagnosis was made in 755 (33.3%) patients. Gadodiamide injection was shown to be safe and well tolerated. It represents a nonionic alternative to the current products for MRI of the central nervous system.

Key words

Gadodiamide Safety Adverse events Central nervous system Efficacy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradley WG, Yuh WTC, Bydder GM (1993) Use of MR imaging contrast agents in the brain. J Magn Reson Imaging 3:199–218Google Scholar
  2. 2.
    Runge VM, Carollo BR, Wolf CR, Nelson KL, Gelblum DY (1989) GdDTPA—a review of clinical indication in central nervous system magnetic resonance imaging. Radiographics 9: 929–935Google Scholar
  3. 3.
    Brant-Zadwadski M, Berry I, Osaki L, Brasch R, Murovic J, Norman D (1986) GdDTPA in clinical MR of the brain. 1. Intraaxial lesions and normal structures. AJNR 7:781–788Google Scholar
  4. 4.
    Berry I, Brant-Zadwadski M, Osaki L, Brasch R, Muroovic J, Norman D (1986) GdDTPA in clinical MR of the brain. 2. Extraaxial lesions and normal structures. AJNR 7:789–794Google Scholar
  5. 5.
    Van Wagoner M, O'Toole M, Quay SC (1990) Non ionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance and efficacy of gadodiamide injection. Invest Radiol 25:S39-S41Google Scholar
  6. 6.
    Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H (1993) Preclinical safety assessement and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28:S28-S43Google Scholar
  7. 7.
    Chang CA (1993) Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. Invest Radiol 28:S21-S27Google Scholar
  8. 8.
    Sze G, Brant-Zawadzki M, Haughton VM, Maravilla KR, McNamara MT, Kumar AJ, Aisen AM, Dreisbach JN, Bradley WG, Weinreb JC, Drayer BP, Tsuruda JS, Hesselink JR, Johnson CE, Zimmerman RD, Weingast GR (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699Google Scholar
  9. 9.
    Greco A, McNamara MT, Lanthiez P, Quay SC, Michelozzi G (1990) Gadodiamide injection: non-ionic gadolinium chelate for MR imaging of the brain and spine. Phase II-III clinical trials. Radiology 176:451–456Google Scholar
  10. 10.
    Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Svaland MG (1993) A double blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MR examinations of the central nervous system. Neuroradiology 35:173–177Google Scholar
  11. 11.
    Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35: 490–494Google Scholar
  12. 12.
    Myhr G, Rinck PA, Borseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33:405–409Google Scholar
  13. 13.
    Svaland MG, Lundby B, Kristoffersen DT (1994) Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system. J Magn Reson Imaging 4:419–423Google Scholar
  14. 14.
    Lundby B, Berg KJ, Lien HH, Aamdal S (1993) A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging. Br J Radiol 66:871–876Google Scholar
  15. 15.
    Goldstein HA, Kashanian FK, Blummetti RF, Holyoak WL, Hugo FP, Blumenfield DM (1990) Safety assessment of gadopentetate dimeglumine in US. clinical trials. Radiology 174:17–23Google Scholar
  16. 16.
    Neiss AC, Le Mignon MM, Vitry A, Caillé JM (1991) Efficacité et tolérance du DOTA-Gd lors d'une enquête multicentrique européenne: résultats préliminaires sur 4169 cas. Rev Im Med 3:383–387Google Scholar
  17. 17.
    Tishler S, Hoffman JC (1993) Anaphylactoid reactions to iv gadopentetate dimeglumine. AJNR 174:17–23Google Scholar
  18. 18.
    Tardy B, Guy C, Barral G, Page Y, Ollagnier M, Bertrand JC (1992) Anaphylactic shock induced by intravenous gadopentetate dimeglumine. Lancet 339:494Google Scholar
  19. 19.
    Shellock F, Hahn P, Mink JH, Itskovich E (1993) Adverse reaction to intravenous gadoteridol. Radiology 189:151–152Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • V. Aslanian
    • 1
  • H. Lemaignen
    • 1
  • P. Bunouf
    • 1
  • M. G. Svaland
    • 2
  • A. Borseth
    • 2
  • B. Lundby
    • 2
  1. 1.Laboratoires Nycomed SAParisFrance
  2. 2.Nycomed Imaging ASOsloNorway

Personalised recommendations